


To provide long-term capital growth.
| Name | % Net Assets |
|---|---|
| Concurrent Technologies | 4.7% |
| AstraZeneca | 4.5% |
| Wilmington | 4.3% |
| Glaxosmithkline | 4.0% |
| Spirax Sarco Engineering | 3.9% |
| RWS Holdings | 3.9% |
| Cobham | 3.7% |
| Next Fifteen Communications | 3.6% |
| Brooks MacDonald | 3.2% |
| Renishaw | 3.2% |
| Key | % Net Assets |
|---|---|
| 4.7% | |
| 4.5% | |
| 4.3% | |
| 4.0% | |
| 82.5% |
| Date | 20-Aug-2025 |
|---|---|
| Bid | 463.28p |
| Offer | 467.26p |
| Currency | GBP |
| Change | 0.47p |
| % | 0.10% |
| YTD change | -17.36p |
| YTD % | -3.60% |
| Fund Inception | 11/11/2005 |
|---|---|
| Fund Manager | Anthony Cross / Julian Fosh |
| Minimum Investment | |
|---|---|
| Initial | £2500 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.75% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.28 |
You are here: research